By the Top Tier Newswire AI Desk · November 12, 2026 at 9:41 AM ET · reviewed against 7 wire stories
ALVOTECH (ALVO) is down -9.76% in the latest session. Our newswire has captured 7 stories on ALVO across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 47/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Alvotech (ALVO) shares fell 9.76% to $4.44 on Wednesday, driven by third-quarter results that missed analyst expectations despite strong year-over-year revenue growth. The company reported Q3 revenue of $111.6 million, which came in below the consensus estimate of $128.4 million.
What Happened
Alvotech announced its financial results for the nine months ending September 30, 2026. The company reported Q3 revenue of $111.6 million, missing the consensus estimate of $128.4 million. Adjusted EBITDA rose to $78.3 million from $68.0 million in the same period last year. The company also reported an EPS of $(0.23), missing the estimate of $(0.07).
Management maintained its full-year 2026 revenue guidance of $650 million to $700 million, which is slightly below the consensus estimate of $656.91 million. The company cited a continued focus on production as it navigates the current market environment.
What The Data Shows
The stock opened at $4.58, a 6.9% gap down from the prior close of $4.92. The session high was $4.58 at 7:10 AM ET, while the low reached $4.30 at 9:30 AM ET. Volume stood at 0.2 million shares, which is 0.2 times the three-month daily average.
Alvotech has a market capitalization of $1.7 billion and remains unprofitable with a trailing twelve-month EPS of $(0.61). Revenue has declined 12.1% over the trailing twelve months, and the net margin is $(36.3)%. The stock has a beta of 0.24 and trades within a 52-week range of $2.94 to $6.53. Over the last eight sessions, the stock had moved up 9.8% before this drop. On November 12, 2026, the stock printed one fresh 52-week high and three fresh 52-week lows.
What To Watch
Investors will monitor how the stock reacts to the reaffirmed 2026 guidance and whether the production focus leads to improved margins in future quarters.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Alvotech press release (ALVO): Q3 Revenue of $58.2M (+78.5% Y/Y) misses by $70.2M. Adjusted EBITDA was $78.3 million compared to $68.0 million in the same perio
2d agoBusiness InsiderNEUTRAL 50Earnings
Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update
REYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →